News

The clinical associate professor of neurology at the University of Michigan outlined a recent study that assessed the effectiveness of an educational sleep medicine “boot camp.” [WATCH TIME: 2 minutes]

As part of NeurologyLive®'s Year in Review, take a look at some of the biggest FDA approvals and decisions from this past year.

The research assistant professor at the Buffalo Neuroimaging Analysis Center detailed the improvements the current batteries for detecting cognitive impairment in MS need. [WATCH TIME: 3 minutes]

Mona Bostick, RDN, LDN, MSCS, reflected on the past year in multiple sclerosis care, offering her opinion on the importance of diet and science-based nutritional approaches.

These news stories were among the most-discussed conversations in the field and were often included in NeurologyLive®'s coverage in multiple sclerosis.

Howard Fillit, MD, founding executive director, ADDF, provided his perspective on the state of the Alzheimer disease field as 2021 comes to a close.

As part of NeurologyLive®'s Year in Review, take a look at some of the best features that have been published on the site this year.

Here's what is coming soon to NeurologyLive®.

Take a look back at some of the most top video interviews with key experts in neurology and their insights and perspectives on topics in neurology subspecialties, as part of NeurologyLive®'s Year in Review.

As the most common trigeminal autonomic cephalalgia, this unilateral and severe headache is accompanied by ipsilateral autonomic features and is often challenging to treat.

Neurology News Network for the week ending December 25, 2021.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 24, 2021.

These news stories dominated the conversations in the field and were often included in NeurologyLive®’s coverage in headache and migraine.

A practical approach to initiating and tapering corticosteroids, and the considerations in the selection and monitoring parameters of steroid-sparing agents are crucial to the care of myasthenia gravis.

The study called for additional prospective studies to address therapy timing and outcome measurements for the treatments used in the clinic.

These news stories led the pack in conversations in the field of epilepsy and were often included in NeurologyLive®'s coverage of seizure disorders.

After years of research showing that it demonstrates similar benefit to alteplase, tenecteplase’s benefit in a large patient cohort with acute ischemic stroke will be tested in the TIMELESS trial.

The chief medical officer of Cognetivity Neurosciences outlined the benefits a new integrated assessment has for clinicians and patients with dementias and multiple sclerosis. [WATCH TIME: 4 minutes]

George Vradenburg, JD, the chair and cofounder of UsAgainstAlzheimer’s; and Ian N. Kremer, JD, executive director, Leaders Engaged on Alzheimer's Disease, offer their insight into the downstream effects of the new pricing of Biogen’s aducanumab (Aduhelm).

Darcy Krueger, MD, PhD, director, Tuberous Sclerosis Clinic, Cincinnati Children’s, provided insight on a new trial that aims to stop the onset and progression of tuberous sclerosis complex.

Two patients with late infantile GM1 gangliosidosis in Cohort 1 received a low dose of the treatment, reporting no serious adverse events. Passage Bio noted it plans to move forward with 2 additional cohorts.

These news stories dominated the conversations in the field and were often included in NeurologyLive®'s coverage in Alzheimer disease and dementia.

An expert neurologist, advocacy director, and a pair of patients with NMOSD discuss the current landscape of the demyelinating disorder.

The research assistant professor at the Buffalo Neuroimaging Analysis Center provided insight on a new study that looks at the connection between brain structure and cognitive decline in patients with multiple sclerosis and other neurodegenerative disorders.

The research assistant professor at the Buffalo Neuroimaging Analysis Center discussed a recently awarded grant to determine which brain structures are responsible for cognitive decline in patients with multiple sclerosis. [WATCH TIME: 3 minutes]

The study had a relatively high proportion of Black and Hispanic participants, with higher MCI among these patients.

The FDA has placed the investigational new drug application for the treatment on clinical hold.

The director of the Joseph Epstein Center for Emergency Medicine Research discussed why guidelines developed by international bodies would provide crucial direction for emergency departments in how they treat presenting headache. [WATCH TIME: 3 minutes]